ClinicalTrials.gg

Program

HS-20118

A development code.

In Hansoh Pharmaceutical Group's pipeline, oral IL-23R. Its studies are mostly in Psoriasis, led by Hansoh Pharmaceutical Group.

Furthest: phase 2, since Aug 11, 20264 company-led studies, 3 open or runningNext primary completion: Dec 25, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group43 open or runningphase 2since Aug 11, 2026Feb 12, 2025Dec 25, 2026phase 1 · NCT07896915
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20118 (oral IL-23R), phase 2, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2025First study: phase 1 study in PsoriasisFirst studyNCT06846710 · 60 enrolled · United States, New Zealand
  2. Jun 3, 2025Phase 1 study in PsoriasisNCT07033234 · 142 planned · China
  3. Aug 11, 2026Phase 2 study in Moderate to Severe Plaque PsoriasisPhase 2 reachedNCT07765628 · 120 planned
  4. Oct 13, 2026Phase 1 study in Healthy ParticipantsNCT07896915 · 32 enrolled · China

Ahead

  1. Dec 25, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07896915
  2. Feb 28, 2027Primary completion: phase 2 study in Moderate to Severe Plaque PsoriasisNCT07765628

TargetBeta

“oral IL-23R”the company's pipeline, read by Claude · source

Other programs on IL23R

ProgramCompanyFurthest phaseStudies
ABBV-859AbbViephase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07896915Healthy Participants · China1Active, not recruitingDec 25, 202632
NCT07765628Moderate to Severe Plaque Psoriasis2Not yet recruitingFeb 28, 2027120
NCT07033234Psoriasis · China1RecruitingMar 2026142
NCT06846710Psoriasis · United States, New Zealand1CompletedJul 14, 202660

How it is read

Names in the registry

  • “HS-20118”, 5 entries

Codes read as this program: HS20118.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.